Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Sharck Soup -- Ignore unavailable to you. Want to Upgrade?

To: DlphcOracl who wrote (22579)	5/12/2001 9:13:35 PM
From: Sharck	Read Replies (1) \| Respond to of 37746

True story, did you guys know when they started mispronouncing UR-Anus to URanus, it was Dan Rather who refused to read the teleprompt, which read that they had discovered new rings around it. LOL Another one for Mondays watch list: IMCL as a sympathy play to NVS, Novartis ImClone's IMC-C225 With Chemo Shrinks Colorectal Tumors By Beth M. Mantz Of DOW JONES NEWSWIRES SAN FRANCISCO (Dow Jones)--The combination regimen of a new kind of drug and a gold standard chemotherapy agent may offer hope to sufferers with advanced colorectal cancer. Results from a highly-anticipated trial, testing ImClone Systems Inc.'s (IMCL) targeted compound IMC-C225 and irinotecan chemotherapy, have demonstrated the combination produces responses in some patients with advanced colorectal cancer who no longer respond to standard chemotherapy. Presented at the 37th annual meeting of the American Society of Clinical Oncology in San Francisco, the study findings showed that tumors shrank more than 50% in 27 of the 121 patients given the combination regimen. Researchers from Memorial Sloane Kettering Cancer Center in New York considered the 22.5% response rate a major response. They were looking for at least a 15% response rate to conclude the compound induced activity. ___________________________________ ImClone IMC-C225-2: To Be Tested For Prolonged Survival Despite any hard evidence of survival, Memorial Sloan-Kettering's Saltz suspects ImClone's IMC-C225 and irinotecan could prolong survival. However, he said nothing conclusive can be determined until a randomized study compares the combination therapy against a control group. ImClone plans to conduct a national pilot study to test the combination of IMC-C225 and irinotecan in 1200 patients who have never been treated before and haven't developed resistance to any chemotherapy treatments to see if the tumors shrink and survival is extended. The study would begin this summer. Saltz said it would be inappropriate and unethical to test for survival in patients who have become resistant to chemotherapy in a study pitting the combination regimen against irinotecan alone. The patients given irinotecan would derive no benefit from the treatment but would experience the toxic side effects. ImClone isn't waiting for results from the first-line study to file for approval of IMC-C225. The company has spoken with the Food and Drug Administration and plans to submit the first part of its filing in June. As more information is gleaned, the company will add to its application that will receive a shortened review because the FDA granted IMC-C225 fast-track status for its fulfilling an unmet medical need. Usually, the fast-track review lasts six months.